This company listing is no longer active
Pharmaxis Management
Management criteria checks 4/4
Pharmaxis' CEO is Gary Phillips, appointed in Mar 2013, has a tenure of 10.25 years. total yearly compensation is A$738.36K, comprised of 70.1% salary and 29.9% bonuses, including company stock and options. directly owns 0.033% of the company’s shares, worth $8.26K. The average tenure of the management team and the board of directors is 10.5 years and 5.7 years respectively.
Key information
Gary Phillips
Chief executive officer
AU$738.4k
Total compensation
| CEO salary percentage | 70.07% |
| CEO tenure | 10.3yrs |
| CEO ownership | 0.03% |
| Management average tenure | 10.5yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | n/a | n/a | AU$2m |
| Sep 30 2022 | n/a | n/a | AU$2m |
| Jun 30 2022 | AU$738k | AU$517k | -AU$2m |
| Mar 31 2022 | n/a | n/a | -AU$16m |
| Dec 31 2021 | n/a | n/a | -AU$12m |
| Sep 30 2021 | n/a | n/a | -AU$1m |
| Jun 30 2021 | AU$683k | AU$444k | -AU$3m |
| Mar 31 2021 | n/a | n/a | AU$5m |
| Dec 31 2020 | n/a | n/a | -AU$4m |
| Sep 30 2020 | n/a | n/a | -AU$13m |
| Jun 30 2020 | AU$559k | AU$440k | -AU$14m |
| Mar 31 2020 | n/a | n/a | -AU$21m |
| Dec 31 2019 | n/a | n/a | -AU$18m |
| Sep 30 2019 | n/a | n/a | -AU$18m |
| Jun 30 2019 | AU$613k | AU$433k | -AU$20m |
| Mar 31 2019 | n/a | n/a | -AU$27m |
| Dec 31 2018 | n/a | n/a | -AU$12m |
| Sep 30 2018 | n/a | n/a | -AU$22m |
| Jun 30 2018 | AU$776k | AU$424k | AU$6m |
| Mar 31 2018 | n/a | n/a | AU$10m |
| Dec 31 2017 | n/a | n/a | -AU$1m |
| Sep 30 2017 | n/a | n/a | AU$7m |
| Jun 30 2017 | AU$799k | AU$423k | -AU$18m |
| Mar 31 2017 | n/a | n/a | -AU$16m |
| Dec 31 2016 | n/a | n/a | -AU$16m |
| Sep 30 2016 | n/a | n/a | -AU$14m |
| Jun 30 2016 | AU$752k | AU$410k | -AU$16m |
Compensation vs Market: Gary's total compensation ($USD488.46K) is below average for companies of similar size in the US market ($USD740.57K).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
CEO
Gary Phillips (62 yo)
Mr. Gary Jonathan Phillips, BPharm, MBA, serves as Independent Non-Executive Director at Arovella Therapeutics Limited since July 1, 2022. He has been Chief Executive Officer and Managing Director of Pharm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 10.3yrs | AU$738.36k | 0.033% $ 8.3k | |
| CFO & Company Secretary | 20.5yrs | AU$552.04k | 0.13% $ 32.2k | |
| Head of Drug Discovery | 10.8yrs | AU$500.34k | 0.17% $ 42.8k | |
| Head of Medical & Regulatory Affairs - Alliance Management | no data | AU$308.49k | no data | |
| Chief Medical Officer | less than a year | AU$554.26k | no data | |
| General Counsel | no data | no data | no data |
Experienced Management: PMXS.F's management team is seasoned and experienced (10.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 10.3yrs | AU$738.36k | 0.033% $ 8.3k | |
| Non-Executive Director | 3.1yrs | AU$70.00k | no data | |
| Independent Chairman of the Board | 19.9yrs | AU$100.00k | 0.34% $ 86.9k | |
| Member of Scientific Advisory Board | no data | AU$711.06k | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 5.7yrs | no data | no data | |
| Member of Scientific Advisory Board & Non Executive Director | 6yrs | AU$70.00k | 0.0028% $ 701.4 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | less than a year | no data | no data |
Experienced Board: PMXS.F's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/06 04:31 |
| End of Day Share Price | 2023/03/09 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syntara Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anubhav Saxena | Bell Potter |
| Thomas Wakim | Bell Potter |
| Madeleine Williams | Canaccord Genuity |